GLP-1 RAs STEP 1 (2021) : Semaglutide 2.4 ./ 14.9% 68 2.4% (Wilding et al., 2021, NEJM) SURMOUNT-1 (2022) : Tirzepatide (GLP-1/GIP dual agonist) 15 ./ 20.9% (Jastreboff et al., 2022, NEJM) GLP-1 HbA1c () 2 (Hypoglycemia) Glucose-dependent LEADER (liraglutide) SUSTAIN-6 (semaglutide) 2024 FDA Semaglutide (Wegovy) FLOW (2024) semaglutide (MASLD/NAFLD) GLP-1 RAs GLP-1
Almutairi NM, Hilal FM, Bashawyah A, Dammas FA, Yamak Altinpulluk E, Hou J-D, Lin J-A, Varrassi G, Chang K-V, Allam AE-S
The Future of Weight Loss Medications The development of medications like Retatrutide signals exciting progress in weight loss treatment
The researchers noted that each study population, the semaglutide group and the type 2 diabetes group had similarly matched demographics, medical histories, lifestyles, and histories of mental health conditions, including suicidal ideation and behavior
Ganju and coauthors commented, Defining the role of GLP-1 RAs in Crohns disease is critical as obesity prevalence rises and integrated care models across gastroenterology, endocrinology, and obesity medicine become more essential. This study included 546 patients with CD with overweight or obesity who had initiated use of a GLP-1RA and were matched with 546 nonGLP-1RA users from the TriNetX research network
